Jennifer Panagoulias
Head of Regulatory and Policy, Co-director of ABOM
Jennifer has worked in drug development for over 20 years, primarily focused on advancing global development programs for the treatment of rare neurological diseases. Her background and experience working with global regulatory agencies to support diverse drug and biological therapy development programs in both the development and post-marketing strategies greatly benefits the FAST community. She is the co-director of the Angelman Syndrome Outcome Measure and Biomarker Consortium (ABOM) and has recently taken on the role of Chief Operating Officer for AS² Biotherapeutics, focused on accelerating drug development for individuals living with Angelman syndrome. Jennifer resides in Danvers, MA. She has a niece who lives with Angelman syndrome.